Infliximab (Anti-TNF-α)

Product Description: Infliximab (Anti-TNF-α) (Avakine (Anti-TNF-α)) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab (Anti-TNF-α) prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). Infliximab (Anti-TNF-α) has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research[1][2].

Applications: Metabolism-sugar/lipid metabolism

Formula: N/A

References: [1]Lucia A Méndez-García, et al. Infliximab ameliorates tumor necrosis factor-alpha-induced insulin resistance by attenuating PTP1B activation in 3T3L1 adipocytes in vitro. Scand J Immunol. 2018 Nov;88(5):e12716. /[2]Isamu Yamakawa, et al. Inactivation of TNF-α ameliorates diabetic neuropathy in mice. Am J Physiol Endocrinol Metab. 2011 Nov;301(5):E844-52.

Molecular Weight: N/A

Compound Purity: 99.00

Research Area: Cancer; Metabolic Disease; Inflammation/Immunology; Neurological Disease

Target: TNF Receptor

• Artikelnummer: MEXHY-P9970A-10
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P9970A-10
• Verpackungseinheit: 10 mg
• Mengeneinheit: STK
• Konjugat: Unconjugated